WebPrice To Cash Flow is a widely used stock evaluation measure. Find the latest Price To Cash Flow for BioXcel Therapeutics (BTAI) WebApr 12, 2024 · The latest price target for BioXcel Therapeutics ( NASDAQ: BTAI) was reported by Jefferies on March 10, 2024. The analyst firm set a price target for $22.00 …
BioXcel Therapeutics (BTAI) Price To Cash Flow - Zacks.com
WebJul 26, 2024 · Recently, the Street’s analysts have tapped three stocks they see as long-term winners – but with low share value right now. According to TipRanks' database, these are Strong Buy stocks, featuring... rob sally face
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Director Krishnan …
WebApr 11, 2024 · BTAI has been the topic of several research reports. The Goldman Sachs Group raised their price target on shares of BioXcel Therapeutics from $16.00 to $26.00 and gave the company a “neutral ... WebApr 6, 2024 · The price target raised to $80 per share is four times as large as the last closing price. BXCL501, the treatment identified as Igalmi after its FDA approval, is … WebApr 11, 2024 · Summit Therapeutics - SMMT Stock Forecast, Price & News $1.53 -0.04 (-2.55%) (As of 04/6/2024 12:00 AM ET) Compare Today's Range $1.51 $1.61 50-Day Range $1.38 $3.88 52-Week Range $0.66 $5.78 Volume 1.17 million shs Average Volume 2.79 million shs Market Capitalization $1.07 billion P/E Ratio N/A Dividend Yield N/A Price … rob salter-church pwc